Brivanib is a dual vascular endothelial growth factor receptor 2 (VEGFR-2)/fibroblastic growth factor receptor 1 (FGFR1) kinase inhibitor, which reduced hepatic fibrosis and activation of stellate cells through the inhibition of VEGF, FGF, and platelet-derived growth factor (PDGF) signaling in preclinical research [27,28,29]. Here, VEGFA is linked to Hepatic fibrosis.